Israeli Startup QuantHealth Raises $45 Million to Revolutionize Drug Development with AI

Israeli startup QuantHealth announced it has raised $45 million to expand its artificial intelligence platform designed to simulate clinical trials before they begin. The platform aims to reduce failure rates in drug development and shorten research timelines by allowing pharmaceutical companies to virtually test and optimize clinical trial designs in advance.

Drug development is notoriously lengthy, costly, and complex, with many drugs failing during clinical trials despite years of investment and billions of dollars spent. QuantHealth’s AI models predict how different patient populations might respond to treatments, identify weaknesses in trial design, and suggest improvements before recruiting any participants. This approach could lower the risk of failure, reduce development time, and cut significant costs for drug companies, ultimately accelerating the delivery of new therapies to patients.

The newly raised funds will be used to enhance the next generation of AI models, expand data repositories, and simulate trials across a broader range of diseases. QuantHealth’s platform has already simulated over 600 clinical trials in more than 30 medical indications, including cancer, cardiovascular, and inflammatory diseases. The company plans to extend coverage to over 40 diseases and broaden its product offerings to support pharmaceutical companies from trial planning through commercial drug launch.

QuantHealth emphasizes that its technology does not replace human clinical trials, which remain essential for drug approval. Instead, it assists researchers and companies in making better-informed decisions during trial design to reduce costly errors and increase the likelihood of successful outcomes. Experts believe AI could become a central tool in drug development, helping innovative treatments reach patients faster in the coming years.